Smart Ring Blood Pressure Monitor Earns Place in Official Hypertension Guidelines
South Korea's hypertension guidelines now recommend cuffless ring monitors, marking a milestone for wearable BP tracking in clinical practice.
Summary
South Korea's leading hypertension authority has officially recommended cuffless ring-type blood pressure monitors in its 2026 guidelines. Sky Labs' CART BP pro, a ring device using AI-powered light-sensing technology, earned a Class IIb recommendation for out-of-office blood pressure monitoring. Clinical trials showed it matched the accuracy of traditional 24-hour cuff-based monitoring and met international accuracy standards. The device has already been prescribed over 250,000 times across nearly 2,000 hospitals in South Korea. Doctors and guideline authors highlighted its ability to detect dangerous nocturnal and morning blood pressure spikes that single office readings routinely miss, while being far more comfortable than traditional cuff monitors worn overnight.
Detailed Summary
Blood pressure monitoring is one of the most critical tools in cardiovascular disease prevention, yet traditional methods are often inconvenient, disruptive to sleep, and limited to snapshots rather than continuous data. A new development from South Korea may represent a meaningful shift in how hypertension is tracked and managed.
The Korean Society of Hypertension has included ring-type cuffless blood pressure monitors in its 2026 clinical guidelines, recommending them as a Class IIb option for out-of-office monitoring. This marks the first time this wearable technology has been formally endorsed by a major national hypertension body, lending significant clinical credibility to the approach.
The device at the center of this milestone is Sky Labs' CART BP pro. It uses photoplethysmography, a light-based sensing method, combined with AI deep learning to measure blood pressure continuously over 24 hours. In comparative clinical trials, the device demonstrated accuracy on par with standard ambulatory blood pressure monitoring and met the ISO 81060-2:2018 international accuracy threshold, the benchmark used to validate medical-grade BP devices.
A key clinical advantage is the ring's ability to detect nocturnal and morning hypertension, two patterns strongly linked to cardiovascular risk but routinely missed by single office readings. Traditional cuff-based ambulatory monitors, while effective, cause sleep disruption that can itself distort nighttime readings. A comfortable ring worn overnight removes that confounding factor.
The CART BP pro received national health insurance reimbursement in South Korea in June 2024 and has since been prescribed more than 250,000 times across approximately 1,920 hospitals and clinics. While this guideline inclusion is encouraging, the Class IIb designation indicates moderate rather than strong evidence, and broader international validation will be needed before global adoption. Still, for health-conscious individuals monitoring cardiovascular risk, this signals wearable BP tracking is entering legitimate clinical territory.
Key Findings
- Ring-type cuffless BP monitor earns first-ever Class IIb recommendation in South Korean hypertension guidelines.
- CART BP pro matched 24-hour ambulatory monitoring accuracy and met ISO 81060-2:2018 international standards in clinical trials.
- Continuous ring monitoring detects nocturnal and morning hypertension patterns that single office readings consistently miss.
- Device prescribed over 250,000 times and deployed in nearly 2,000 South Korean hospitals since insurance reimbursement in 2024.
- Cuffless ring design eliminates sleep disruption caused by traditional overnight cuff-based ambulatory monitors.
Methodology
This is a news report based on a company announcement and official guideline publication from the Korean Society of Hypertension. Evidence basis includes comparative clinical trial data and ISO accuracy validation, though the article does not link directly to peer-reviewed publications. Source credibility is moderate; independent review of the underlying trial data is advisable.
Study Limitations
The article relies heavily on Sky Labs' own claims and does not cite specific peer-reviewed studies for independent verification. The Class IIb guideline designation reflects moderate, not strong, evidence and applies only to Korean clinical standards. International regulatory approval and broader multi-population validation studies have not been confirmed in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.